ALUR vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ALUR exhibits severe financial distress with a Piotroski F-Score of 0/9, indicating extreme weakness in operational and financial health. The Altman Z-Score is unavailable, but the company's negative profitability, collapsing revenue growth, and negative ROA (-71.87%) signal high distress risk. Despite a gross margin of 60.99%, the company is losing money at an accelerating rate, with a -187.87% profit margin and -362.30% operating margin. The stock trades at a deeply discounted price of $0.53, but this reflects a market pricing in failure rather than value. Analysts have a target of $5.50, but with no consensus recommendation and a 5-year return of -99.8%, the outlook remains bleak.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ALUR vs MRK: Head-to-Head Comparison
This page compares Allurion Technologies Inc. (ALUR) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.